Pfizer (NYSE:PFE) Stock Price Up 3% – Still a Buy?

Pfizer Inc. (NYSE:PFE)’s stock price shot up 3% on Wednesday. The stock traded as high as $29.49 and last traded at $29.2170. 39,282,235 shares were traded during trading, a decline of 2% from the average session volume of 40,269,410 shares. The stock had previously closed at $28.37.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Broad IDWeek 2026 pipeline update: Pfizer plans to present more than 50 abstracts, including 12 oral presentations, covering pneumococcal disease, RSV, COVID-19 and Lyme disease. The volume of upcoming clinical data gives investors multiple potential catalysts beyond the company’s COVID-era products. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: Next-generation vaccine progress: Pfizer has begun a Phase 3 trial for a next-generation pediatric pneumococcal vaccine, potentially extending the growth runway for its vaccines business. Investors are also watching Phase 3 Lyme vaccine results and additional real-world vaccine data. Pfizer’s Next-Gen Pneumococcal Shot Enters Key Phase 3 Test
• Positive Sentiment: New external innovation deal: Pfizer’s collaboration and licensing agreement with Enodia Therapeutics gives it access to a Sec61 inhibitor platform and adds a new small-molecule discovery program. Pfizer will oversee clinical, regulatory and commercial development, although the financial and development risks remain significant. What Is Pfizer Really Gaining From Its Sec61 Drug Discovery Deal?
• Positive Sentiment: Income support and improving outlook: Pfizer’s roughly 6% dividend yield, recently declared quarterly dividend of $0.43 per share, positive recent clinical updates and improved earnings guidance make the stock attractive to income-focused investors while the pipeline develops. Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline
• Neutral Sentiment: Risks remain: Commentary highlights Pfizer’s elevated dividend payout ratio, while the median analyst price target of about $27 trails the stock’s recent trading level. These factors may limit further upside unless clinical execution and earnings growth improve. Pfizer Pays Out Over 226% of Earnings

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PFE shares. Scotiabank boosted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.72.

Pfizer Stock Performance

The firm’s 50 day simple moving average is $27.81 and its 200 day simple moving average is $26.52. The firm has a market capitalization of $166.53 billion, a price-to-earnings ratio of 38.44, a PEG ratio of 1.92 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE purchased a new stake in Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. increased its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. Nykredit A S purchased a new stake in Pfizer in the 2nd quarter valued at about $205,774,000. Assenagon Asset Management S.A. lifted its position in Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after buying an additional 5,829,204 shares during the last quarter. Finally, State Street Corp lifted its position in Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after buying an additional 5,501,032 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.